Gene-Edited immune cells take on tough lymphoma
NCT ID NCT00368082
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 29 times
Summary
This early-phase study tests a new treatment for people with relapsed lymphoma tied to the Epstein-Barr virus. The therapy uses the patient's own immune cells, modified to resist a substance tumors use to hide. The goal is to find a safe dose and see if these cells can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Texas Childrens Hospital
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.